Data on Pfizer's monthly injectable GLP-1 drug paves way for broad Phase 3 obesity program

Pfizer's $10 billion acquisition of Metsera's monthly injectable GLP-1 drug is now in a Phase 3 program spanning 10 pivotal studies this year. While Pfizer's pipeline spans internally developed and licensed assets targeting other targets, the drugmaker said the Metsera drug is the cornerstone of its obesity strategy to pursue monotherapies and combination treatments.

The post Data on Pfizer’s monthly GLP-1 shot paving the way for broad Phase 3 plan for obesity appeared first on MedCity News.